Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.53 |
| ▸ | CTSL | P07711 | 4/20 | 0.47 |
| ▸ | ACE | P12821 | 2/20 | 0.46 |
| ▸ | CTSB | P07858 | 3/20 | 0.45 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8190987 | 1.00 | CTSS (0.53) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL1908584 | 1.00 | CTSS (0.53) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL3868893 | 1.00 | CTSS (0.53) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL2249922 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL5765651 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL2249917 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL5765656 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL5743142 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL5743140 | 0.93 | CTSL (0.50) | CTSSCTSKCTSLACECTSB | |
| SCHEMBL14885697 | 0.88 | CTSK (0.40) | CTSSCTSKCTSLACEBCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8946481-B2 | Process for preparing biaryl substituted 4-amino butyric acid or derivatives thereof and their use in the production of NEP inhibitors | NOVARTIS AG (CH) | 2015-02-03 | — | — | US | disclosed |
| EP-2066618-B1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2009-12-31 | — | — | US | disclosed |
| EP-2066618-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | Novartis AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-1903027-A1 | Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors | Novartis AG (CH) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008031567-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
| EP-0660840-B1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA GEIGY AG (CH) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996026729-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES AS ECE INHIBITORS | CIBA-GEIGY AG (CH) | 1996-09-06 | — | — | WO | disclosed |
| US-5550119-A | ENDOTHELIN-CONVERTING ENZYM INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1996-08-27 | — | — | US | disclosed |
| EP-0660840-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES. | CIBA GEIGY AG (CH) | 1995-07-05 | — | — | EP | disclosed |
| WO-1994005677-A1 | PHOSPHONO SUBSTITUTED TETRAZOLE DERIVATIVES | CIBA-GEIGY AG (CH) | 1994-03-17 | — | — | WO | disclosed |
| US-5273990-A | 5-Phosphonomethyleneamino aryl-substitued alkylene-1H-tetazoles | CIBA-GEIGY CORPORATION (US) | 1993-12-28 | — | — | US | disclosed |
| US-5250522-A | Neutral endopeptidase inhibitors; cardiovascular disorders | CIBA-GEIGY CORPORATION (US) | 1993-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066101-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CTSS 1512/4885CTSK 3062/4885CTSL 1962/4885 |
| US-20090326066-A1 | PROCESS FOR PREPARING BIARYL SUBSTITUTED 4-AMINO-BUTYRIC ACID OR DERIVATIVES THEREOF AND THEIR USE IN THE PRODUCTION OF NEP INHIBITORS | MME, REN, BCAT2 | CTSS 1291/4885CTSK 2982/4885CTSL 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.